We evaluated whether tibolone had an adverse effect on the progression free survival and overall survival of epithelial ovarian cancer patients.
Forty-two tibolone users and 33 non-users who had been surgically managed for epithelial ovarian cancer at Gil Medical Center, Inchon, Korea, from January 1997 to December 2003 were reviewed retrospectively.
There were no statistically significant differences in age, stage, histology, grade and surgical optimality between tibolone users and non-users. The progression free survival at 36 months was 60.0% among the users compared with 61.5% among the non-users (p = 0.92). There was also no significant difference in the overall survival between two groups (p = 0.30). For stage IIIc patients according to tibolone using, there were no significant differences in the progression free survival (p = 0.86) and overall survival (p = 0.36) between tibolone users and non-users.
There was no evidence that tibolone had detrimental effects on the progression free survival and overall survival of epithelial ovarian cancer patients. So, tibolone could be used in these patients.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
2002 Annual report of the Korea central cancer registry (2002.1–2002.12). Republic of Korea: Korea Central Cancer Registry, Ministry of Health and Welfare; 2003.
- Carcinoma of the ovary. Annual report on the results of treatment of gynecological cancer, vol 23. International Federation of Gynecology and Obstetrics.J Epidemiol Biostat. 1998; 3: 75-102
- Epithelial ovarian cancer—practical gynecologic oncology.3rd ed. Lippincott Williams & Wilkins, Philadelphia2005
- Improved survival for women ovarian cancer.Proc Soc Gynecol Oncol. 1999; (Abstract 136)
- Gynecol Oncol. 1986; 25: 383
- Hormone replacement therapy and survival after surgery for ovarian cancer.BMJ. 1991; 302: 259-262
- Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial.Cancer. 1999; 86: 1013-1018
- Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival.Menopause. 2001; 8: 70-75
- Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancer in white women. Collaborative Ovarian Cancer Group.Am J Epidemiol. 1992; 136: 1184-1203
- Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis.Obstet Gynecol. 1998; 92: 472-479
- Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis.Br J Obstet Gynecol. 1990; 97: 1080-1086
- Tibolone for postmenopausal women: systemic review of randomized trials.J Clin Endocrinol Metab. 1993; 7: 183-202
- Production and actions of estrogens.N Engl J Med. 2002; 31: 340-352
- Effects of tibolone on the breast.Eur J Obstet Gynecol Reprod Biol. 1998; 80: 235-238
- Effects of progestagens and Org OD14 in in vitro and in vivo tumor models.J Steroid Biochem Mol Biol. 1994; 49: 311-318
- Tibolone actions on normal and breast cancer cells.Eur J Cancer. 2000; 36: 76-77
Accepted: January 25, 2006
Received in revised form: January 20, 2006
Received: August 8, 2005
© 2006 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.